# Congo's Ebola Outbreak Has Passed 11,000 Cases. That Does Not Tell Us Whether Transmission Is Slowing.

> MKNIRALO — Health — DRC · Ebola

- Published: 2026-11-11
- Estimated reading time: 6 minutes
- Byline: Zuri — Public Health Surveillance Observer
- Byline disclosure: Zuri is a house editorial byline maintained by MKNIRALO, not a claim of an independently verified individual. It does not imply a medical licence, personal examination of patients, laboratory employment, nationality or firsthand field reporting. This coverage is informational and not medical advice.
- Author profile: https://mkniralo.com/authors/zuri/
- Tags: Ebola, Democratic Republic of the Congo, Public Health, Africa, Disease Surveillance, Vaccines, Humanitarian Response
- Cover image: https://mkniralo.com/images/drc-ebola-passes-11000-cases-milestone-2026.svg

Government data reported November 10 put DRC at 11,042 confirmed Bundibugyo Ebola cases and 5,387 deaths; a cumulative milestone cannot determine whether transmission is slowing.

The Democratic Republic of the Congo's Bundibugyo Ebola outbreak has crossed 11,000 confirmed infections. Figures from the government, reported by Reuters on November 10, put the tally at 11,042 confirmed cases and 5,387 deaths. The figures describe an exceptionally large emergency. They do not, by themselves, establish whether the pace of new infections has accelerated, stabilized or started to decline.

An earlier European Centre for Disease Prevention and Control (ECDC) assessment, published November 10 using data through November 8, recorded 10,990 confirmed cases and 5,354 related deaths. Those are two snapshots with different reporting cutoffs, not competing simultaneous measurements. Authorities also revise and harmonize records as investigations continue. The harder question is what happens in individual health zones after a headline threshold is crossed.

## What the latest numbers actually establish

The November 10 government figures, as relayed by Reuters, establish that the reported cumulative count passed 11,000. They do not supply a comparable breakdown of newly detected infections by health zone, nor do they demonstrate an outbreak-wide decline. ECDC's earlier November 8-cutoff data identified affected areas across eight provinces and recorded 70 additional confirmed cases and 31 deaths compared with the previous day's cutoff. Those increments belong to ECDC's defined reporting interval, not automatically to the later government tally.

A cumulative count does not decrease when daily infections slow. It can keep climbing as earlier infections are confirmed, or as surveillance reaches previously missed communities. By the same reasoning, an improvement in one district can coincide with new transmission in another. A reliable trend assessment needs consistent reporting periods, case definitions, laboratory-confirmation practices and health-zone-level data. It also needs to account for delayed identification and revisions to historical totals.

Sources:
- [Congo’s Ebola cases surpass 11,000, government data show](https://www.reuters.com/business/healthcare-pharmaceuticals/congos-ebola-cases-surpass-11000-government-data-show-2026-11-10/) — Reuters
- [Ebola disease outbreak caused by Bundibugyo virus – Multi-country – 2026](https://www.ecdc.europa.eu/en/public-health-events/2026-eip-00026/2026-11-10) — ECDC
- [Ebola disease caused by Bundibugyo virus – DRC, Kenya and Nigeria](https://www.who.int/emergencies/disease-outbreak-news/item/2026-DON625) — WHO

## Why Bundibugyo Ebola presents a particular challenge

The outbreak is caused by Bundibugyo virus, which causes a form of Ebola disease distinct from disease caused by Ebola virus, formerly referred to as the Zaire species. This distinction determines what can be said about medical countermeasures. In its November 9 vaccine guidance, the World Health Organization said that no vaccine is licensed specifically for Bundibugyo virus disease. Ervebo is licensed against disease caused by Ebola virus, but its effectiveness against Bundibugyo disease in people has not been established.

An absence of a licensed species-specific vaccine does not mean that patients cannot benefit from medical care. WHO emphasizes rapid detection, supportive clinical management, isolation where appropriate, infection prevention and control, safe burials, contact tracing and community cooperation. No specific treatment is currently approved for Bundibugyo disease, although trials are testing candidate approaches. Clinical care and access to trusted services remain central while that evidence is collected.

Sources:
- [Ebola disease caused by Bundibugyo virus – DRC, Kenya and Nigeria](https://www.who.int/emergencies/disease-outbreak-news/item/2026-DON625) — WHO
- [Ebola vaccines](https://www.who.int/news-room/questions-and-answers/item/ebola-vaccines) — WHO
- [Two new candidate vaccines to join Ebola trial as treatment research advances](https://www.who.int/tokelau/news/detail-global/04-11-2026-two-new-candidate-vaccines-to-join-ebola-trial-as-treatment-research-advances) — WHO

## The geography of an outbreak is not the geography of equal risk

WHO's November 6 outbreak bulletin used data through November 3 to identify confirmed infections in 67 health zones across eight provinces, with active transmission in 51 zones. WHO described modest improvements in some locations alongside continuing high-level transmission overall. ECDC's later November 8-cutoff dataset still identified eight affected provinces, but its count of 67 zones refers to zones affected since the outbreak began—not an independently updated count of active zones on November 8. The two measures should not be conflated.

Elsewhere, ECDC reported nine confirmed linked cases in Kenya, including two deaths, as of November 8, with the last case in that cluster reported October 20. It also documented a case reported in Nigeria on October 20. These incidents illustrate why cross-border detection and contact monitoring matter, but they do not by themselves prove sustained community transmission in either country. ECDC assessed the overall risk for the general population in the European Union or European Economic Area as very low in its October 23 threat assessment brief.

Sources:
- [Ebola disease outbreak caused by Bundibugyo virus – Multi-country – 2026](https://www.ecdc.europa.eu/en/public-health-events/2026-eip-00026/2026-11-10) — ECDC
- [Ebola disease caused by Bundibugyo virus – DRC, Kenya and Nigeria](https://www.who.int/emergencies/disease-outbreak-news/item/2026-DON625) — WHO
- [Importation of Ebola disease cases caused by Bundibugyo virus to Kenya and Nigeria](https://www.ecdc.europa.eu/sites/default/files/documents/importation-ebola-tab.pdf) — ECDC

## Why insecurity and delayed care matter

The timing and location of deaths are among the indicators that the cumulative case figure cannot explain. WHO reported on November 6 that, among 512 deaths recorded since October 21, 335 occurred in communities and 177 in treatment centers. These are deaths within that specific reporting window, not the overall cumulative death total. The substantial community share points to problems of case recognition, safe transport, access to care and trust in response services; it does not identify a single cause for every death outside a facility.

Violence can further disrupt those services. The Associated Press reported an attack on Cantine in North Kivu, citing a hospital director who said 180 patients fled the local hospital, including suspected Ebola cases and one confirmed case. AP attributed responsibility for the attack to allegations made by a local civil-society representative; that attribution should not be recast as an independently established finding. The documented public-health concern is that patients and monitored contacts can become difficult to locate when care and isolation are interrupted.

Sources:
- [Ebola disease caused by Bundibugyo virus – DRC, Kenya and Nigeria](https://www.who.int/emergencies/disease-outbreak-news/item/2026-DON625) — WHO
- [IS-linked militants kill at least 33 in eastern Congo village attack, civil society says](https://apnews.com/article/congo-attack-militants-village-deaths-8c1714ba93398184703e5866d8b9c0c6) — AP

## Vaccine research is moving, but it is not a finished solution

WHO said on November 4 that two Bundibugyo-focused vaccine candidates—ChAdOx1 BDBV, developed by Oxford with the Serum Institute of India, and Moderna's mRNA-1469—had been recommended for inclusion in the adaptive Tumaini clinical trial, subject to national approvals. The trial was already evaluating Ervebo against Bundibugyo disease as a research question, not as proof of cross-protection. The aim is to determine safety and effectiveness through evidence rather than assumption.

The development program also includes potential treatments under investigation, including monoclonal antibodies and antivirals. A candidate's selection for testing, a trial's launch and an eventual demonstration of protection are different milestones. Even a successful study would leave production, distribution, staff safety, patient follow-up and community acceptance to be addressed. Research offers a route to stronger tools; it cannot replace basic outbreak response while its results remain pending.

Sources:
- [Ebola vaccines](https://www.who.int/news-room/questions-and-answers/item/ebola-vaccines) — WHO
- [Two new candidate vaccines to join Ebola trial as treatment research advances](https://www.who.int/tokelau/news/detail-global/04-11-2026-two-new-candidate-vaccines-to-join-ebola-trial-as-treatment-research-advances) — WHO

## What to watch after the 11,000-case threshold

A useful next assessment would compare new confirmed cases over matching surveillance intervals and identify whether transmission is shrinking or persisting in specific health zones. Other signals include the number of active zones, the proportion of deaths occurring outside treatment centers, how many known contacts remain under follow-up, and whether people with suspected infection can obtain timely testing and care. ECDC reported 79.2% of identified contacts under follow-up in its November 8-cutoff DRC assessment—a useful operational measure, but not proof that every exposure was identified.

The outbreak has not been declared over, and crossing a round number is not evidence that it is peaking. The most defensible conclusion on November 11 is narrower: the government's November 10 cumulative figures document a major toll, while WHO and ECDC describe continuing, uneven transmission and substantial barriers to care. The next headline should be shaped by dated surveillance and the response on the ground, rather than by the emotional force of 11,000 alone.

Sources:
- [Congo’s Ebola cases surpass 11,000, government data show](https://www.reuters.com/business/healthcare-pharmaceuticals/congos-ebola-cases-surpass-11000-government-data-show-2026-11-10/) — Reuters
- [Ebola disease outbreak caused by Bundibugyo virus – Multi-country – 2026](https://www.ecdc.europa.eu/en/public-health-events/2026-eip-00026/2026-11-10) — ECDC
- [Ebola disease caused by Bundibugyo virus – DRC, Kenya and Nigeria](https://www.who.int/emergencies/disease-outbreak-news/item/2026-DON625) — WHO

## About this article

This article reflects the public sources available on the publication and update dates shown above. For developing stories, follow the linked source pages for subsequent statements or decisions.

## Sources and further reading

- [Congo’s Ebola cases surpass 11,000, government data show](https://www.reuters.com/business/healthcare-pharmaceuticals/congos-ebola-cases-surpass-11000-government-data-show-2026-11-10/) — Reuters (published 2026-11-10) (accessed 2026-11-11)
- [Ebola disease outbreak caused by Bundibugyo virus – Multi-country – 2026](https://www.ecdc.europa.eu/en/public-health-events/2026-eip-00026/2026-11-10) — ECDC (published 2026-11-10) (accessed 2026-11-11)
- [Ebola disease caused by Bundibugyo virus – DRC, Kenya and Nigeria](https://www.who.int/emergencies/disease-outbreak-news/item/2026-DON625) — WHO (published 2026-11-06) (accessed 2026-11-11)
- [Ebola vaccines](https://www.who.int/news-room/questions-and-answers/item/ebola-vaccines) — WHO (published 2026-11-09) (accessed 2026-11-11)
- [Two new candidate vaccines to join Ebola trial as treatment research advances](https://www.who.int/tokelau/news/detail-global/04-11-2026-two-new-candidate-vaccines-to-join-ebola-trial-as-treatment-research-advances) — WHO (published 2026-11-04) (accessed 2026-11-11)
- [IS-linked militants kill at least 33 in eastern Congo village attack, civil society says](https://apnews.com/article/congo-attack-militants-village-deaths-8c1714ba93398184703e5866d8b9c0c6) — AP (published 2026-11-06) (accessed 2026-11-11)
- [Importation of Ebola disease cases caused by Bundibugyo virus to Kenya and Nigeria](https://www.ecdc.europa.eu/sites/default/files/documents/importation-ebola-tab.pdf) — ECDC (published 2026-10-23) (accessed 2026-11-11)